Grupo de Evaluación de Tecnologías y Políticas en Salud, Clinical Research Institute - School of Medicine, National University of Colombia, Bogotá DC, Colombia.
Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):111-9. doi: 10.1177/1533317512470209. Epub 2013 Jan 2.
Alzheimer's disease dementia (AD dementia) is one of the most common neurodegenerative diseases worldwide, with a growing incidence during the last decades. Clinical diagnosis of cognitive impairment and presence of AD biomarkers have become important issues for early and adequate treatment. We performed a systematic literature search and quality appraisal of AD dementia guidelines, published between 2005 and 2011, which contained diagnostic recommendations on AD dementia. We also analyzed diagnostic recommendations related to the use of brief cognitive tests, neuropsychological evaluation, and AD biomarkers. Of the 537 retrieved references, 15 met the selection criteria. We found that Appraisal of Guidelines Research and Evaluation (AGREE)-II domains such as applicability and editorial independence had the lowest scores. The wide variability on assessment of quality of evidence and strength of recommendations were the main concerns identified regarding diagnostic testing. Although the appropriate methodology for clinical practice guideline development is well known, the quality of diagnostic AD dementia guidelines can be significantly improved.
阿尔茨海默病性痴呆(AD 痴呆)是全世界最常见的神经退行性疾病之一,在过去几十年中发病率不断上升。认知障碍的临床诊断和 AD 生物标志物的出现已成为早期和适当治疗的重要问题。我们对 2005 年至 2011 年间发表的 AD 痴呆指南进行了系统的文献检索和质量评估,这些指南包含了 AD 痴呆的诊断建议。我们还分析了与使用简短认知测试、神经心理学评估和 AD 生物标志物相关的诊断建议。在检索到的 537 篇参考文献中,有 15 篇符合选择标准。我们发现,评估指南研究与评估(AGREE-II)等领域,如适用性和编辑独立性的得分最低。关于诊断检测,主要关注的是对证据质量和建议强度的评估存在很大差异。尽管临床实践指南制定的适当方法众所周知,但 AD 痴呆诊断指南的质量可以得到显著提高。